Hutchmed (HCM) announced that it has completed enrollment of its a Phase II trial of fanregratinib for intrahepatic cholangiocarcinoma patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback